Anti-obesity Drugs Companies | Forecast by 2033

06 Sep 2024

Share :

Table of Content

1. Anti-obesity Drugs Market Growth, Trends and Report Highlights 2. Market Overview 3. Growth Factors 4. Market Dynamics 5. Regional insights 6. Market Potential and Opportunity 7. Anti-obesity Drugs Market Highlights 8. Anti-obesity Drugs Market News: 

Anti-obesity Drugs Market Growth, Trends and Report Highlights

The global anti-obesity drugs market surpassed USD 4.53 billion in 2023 and is predicted to attain around USD 44.01 billion by 2033, growing at a CAGR of 5.53% during the forecast period. The rising awareness about health and its associated co-morbid conditions like diabetes, cardiovascular diseases is expected to contribute to the demand of Anti-Obesity Drugs market. Additionally, the advancements made in the drug technologies and the investments in the R&D sector are poised to grow the market to combat the weight related issues.

Market Overview

Anti-obesity drugs are used in the conditions of overweight or to lose weight. These medications work differently either by reducing appetite, speeding the body’s metabolism or preventing the body from absorbing the fat food. They are categorized mainly into three types based on its action like those that inhibit the fat from being absorbed, those that suppress appetite and those that help the body burn more fat.

The anti-obesity drugs offer various medications to reduce weight and health related diseases and works in different ways by inhibiting the food intake capacity, hanging the neurotransmitter levels that ultimately affects the metabolism. Many healthcare professionals recommend these medications along with lifestyle change and dietary changes.

Growth Factors

• The increasing incidences of obese patients and the rise in chronic diseases like Type 2 diabetes, cardiovascular diseases, cancer is raising the concern for lifestyle changes.
•  For instance, the World Obesity Federation in March 2023 started a campaign named “Changing Perspectives: Let’s Talk About Obesity” on the occasion of World Obesity Day to focus on the misconceptions regarding obesity and guiding towards a healthy lifestyle.
• Many organizations are focusing and implementing various strategies to increase awareness among the population. Moreover, industry players are investing in research and developing various products to tackle the health related issues.
• For example, In June 2023 Eli Lilly Company’s Retatrutide drug was reported to have the potential to treat obesity along with Type 2 diabetes that is injected once a week which works by inhibiting appetite to induce weight loss.
• Also, the growing focus made on the use of personalized medicines keeping in focus the individual differences in genetics, metabolism and lifestyle changes contribute to the market growth. Advancements in the biomarker research and genetic testing enhance of the development of the treatment regimens and pharmacotherapy to optimize the patient outcomes.
• In addition, combination therapies that include the multiple mechanism of action are also gaining demand by targeting various paths involved in metabolism, fat absorption and appetite regulation and enhance the efficacy and minimize the side effects.

Market Dynamics

Increasing incidences of obesity boost the market growth

Obesity is much more common globally, but the rate of incidence varies significantly from country to country. The rise in disease is mostly due to the people’s lifestyle changes and unhealthy diet. But there is no direct correlation between country’s economy and obesity rate; wealthy countries often take initiatives to conduct various programs and campaigns to educate the people about healthy lifestyle and dietary patterns.

Obesity affects the society in various ways both directly and indirectly and with a considerable strain on healthcare and social services. Some of the countries in Europe like Hungary, Malta and Lithuania are mostly affected with the obesity epidemic.

Obesity has become a global epidemic with a death rate of 2.8 million people dying each year due to obesity according to the WHO reports. As obesity continues to rise the need for effective treatment also increases. In addition, the rising demand leads to the more demand of manufacturing of the Anti-Obesity drugs and many companies are focusing on the research and development to manufacture drugs that could meet the rising demand.

For instance, Innovent Biologics Inc., in May 2023, conducted a Phase 2 Clinical study of Mazdutide (IBI362) with a 9 mg dose that resulted in positive outcomes in Chinese adults with obesity. Such advances in the product lead for a better potential and future.

Strict Drug Policies Hinder the Market Growth

Although with the increasing need for the effective anti-obesity medications the strict regulatory policies are one the main reason that stops the market growth. Also, the difficulty in the drug approval process of the anti-obesity drugs that influence many biopharmaceutical companies from investing into the market. Moreover, the increasing R&D cost required for the manufacturing of new anti-obesity drugs restraints the market growth. 

Regional insights

By region North America dominated the anti-obesity drugs market globally in 2023 due to various factors like incidence rates of obesity, approval of new medications by the U.S. FDA and advancements made in the drug development technologies. Additionally the high-income regions with high healthcare infrastructure also contribute to the growth in this region.

• For instance, the region America has the highest prevalence with 62.5% of adults with overweight or obesity. To address the issues of the increase rate of obesity, PAHO promotes and implements policies to improve the diet, physical activity and has also approved the Plan of Action for the Prevention of Obesity in Children and Adolescents. 

The U.S. is expected to lead the anti-obesity drugs market due to the large obese population and the approval of new anti-obesity drugs by the FDA. For instance, the article published by BioPharma in April 2024 reports that the U.S. is expected to grow in the new obesity drug market in the coming years as over the past decades the increase in the obesity population is continuing upward trend.

Asia-Pacific is the fastest growing market for the anti-obesity drugs market during the forecast period due to the prevalence of obesity, sedentary lifestyles and unhealthy food habits. In addition the increasing awareness regarding the obesity and its associated risk like diabetes, heart disease and cancer and the rising medication use in the countries like India, Japan, China and South Korea are contributing for the market growth. 

• For instance, in January 2024, Cipla Ltd. Has launched the drugs for the treatment of diabetes and obesity in India, U.S. as it seeks great opportunity for the formulation of the product. GLP-1 is a big transformation for treating the conditions of diabetes and obesity.

Top Companies in the Anti-obesity Drugs Market: 

• Amgen Inc.
• Alvogen Iceland EHF
• Eli Lilly and Co.
• Empros Pharma AB
• AstraZeneca Plc
• Gelesis Inc.
• ERX Pharmaceuticals Inc.
• GlaxoSmithKline Plc
• Innovent Biologics Inc
• LG Chem Ltd.
• Novo Nordisk AS
• SCOHIA PHARMA Inc.
• VIVUS LLC
• Zydus Lifesciences Ltd.
• Recent Developments

Recent Development in Anti-Obesity by Eli Lilly

Recent Development in Anti-Obesity by Novo Nordisk

Market Potential and Opportunity

A significant shift towards the anti-obesity drugs is due to the rising incidences of morbid obesity. The growing prevalence of morbid obesity is because of factors associated with increased demand of healthcare resources. Also, the procedures like blood withdrawals, X-rays, CT scans and bedside ultrasounds are more time consuming for individuals with morbid obesity. Therefore, the incidences of morbid obesity are expected to drive the market growth during the forecast period.

Anti-obesity Drugs Market Highlights

Anti-obesity Drugs Market News: 

• In February 2022, Pfizer Inc’s study on oral diabetes medication named glucagon-like peptides-1 receptors shows that the medications helps to control type2 diabetes and help in weight loss as obesity is mostly associated with type 2 diabetes.
• In April 2021 Zealand Pharma A/S and Boehringer Ingelheim started the Phase 2 trials of GLP-1/glucagon dual agonist BI 456906 for treating the conditions of overweight and for the non-alcoholic steatohepatitis adults.
• In November 2023, Apollo institute conducted an Anti-Obesity programme named ‘MOULD’ to help weight management. It aims to help patients with a weight loss through 360-degree approach including body composition analysis, physicians consultations, co-morbidity assessments, dietary changes that aim to weight loss of an individual. 

Market Segmentation

By Type

• Prescription Drug
• OTC Drug 

By Distribution Channel

• Hospital Pharmacy
• Retail and Online Pharmacy

Get this report to explore global market size, share, CAGR and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/4896

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308